image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.6292
-4.54 %
$ 60.3 M
Market Cap
-1.97
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ASRT stock under the worst case scenario is HIDDEN Compared to the current market price of 0.629 USD, Assertio Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ASRT stock under the base case scenario is HIDDEN Compared to the current market price of 0.629 USD, Assertio Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ASRT stock under the best case scenario is HIDDEN Compared to the current market price of 0.629 USD, Assertio Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ASRT

image
$0.9$0.9$0.9$0.9$0.8$0.8$0.8$0.8$0.7$0.7$0.7$0.7$0.6$0.6$0.6$0.6$0.5$0.5Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
125 M REVENUE
-17.83%
-24.5 M OPERATING INCOME
89.95%
-21.6 M NET INCOME
93.50%
26.4 M OPERATING CASH FLOW
-46.76%
-48.9 M INVESTING CASH FLOW
-1579.30%
-350 K FINANCING CASH FLOW
99.21%
26.5 M REVENUE
-17.69%
-13.2 M OPERATING INCOME
1.79%
-13.5 M NET INCOME
-29.26%
-12.5 M OPERATING CASH FLOW
-108.57%
-2.94 M INVESTING CASH FLOW
-262.52%
-111 K FINANCING CASH FLOW
-88.14%
Balance Sheet Assertio Holdings, Inc.
image
Current Assets 203 M
Cash & Short-Term Investments 100 M
Receivables 54.1 M
Other Current Assets 48.4 M
Non-Current Assets 82.2 M
Long-Term Investments 0
PP&E 1.71 M
Other Non-Current Assets 80.5 M
35.14 %19.01 %16.99 %28.26 %Total Assets$284.7m
Current Liabilities 115 M
Accounts Payable 14.7 M
Short-Term Debt 0
Other Current Liabilities 100 M
Non-Current Liabilities 49 M
Long-Term Debt 39.9 M
Other Non-Current Liabilities 9.03 M
9.00 %61.08 %24.40 %5.52 %Total Liabilities$163.7m
EFFICIENCY
Earnings Waterfall Assertio Holdings, Inc.
image
Revenue 125 M
Cost Of Revenue 39.2 M
Gross Profit 85.7 M
Operating Expenses 110 M
Operating Income -24.5 M
Other Expenses -2.9 M
Net Income -21.6 M
140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)125m(39m)86m(110m)(24m)3m(22m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
68.61% GROSS MARGIN
68.61%
-19.59% OPERATING MARGIN
-19.59%
-17.27% NET MARGIN
-17.27%
-17.82% ROE
-17.82%
-7.58% ROA
-7.58%
-14.43% ROIC
-14.43%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Assertio Holdings, Inc.
image
120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -21.6 M
Depreciation & Amortization 25.8 M
Capital Expenditures 0
Stock-Based Compensation 5.01 M
Change in Working Capital 5.2 M
Others 34.4 M
Free Cash Flow 26.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Assertio Holdings, Inc.
image
Wall Street analysts predict an average 1-year price target for ASRT of $2.45 , with forecasts ranging from a low of $1.75 to a high of $3 .
ASRT Lowest Price Target Wall Street Target
1.75 USD 178.13%
ASRT Average Price Target Wall Street Target
2.45 USD 289.38%
ASRT Highest Price Target Wall Street Target
3 USD 376.80%
Price
Max Price Target
Min Price Target
Average Price Target
333322221111Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Assertio Holdings, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
70 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
New Strong Sell Stocks for June 18th APLE, ASRT and BOOT have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2025. zacks.com - 2 weeks ago
Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025 LAKE FOREST, Ill., May 19, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the virtual Alliance Global Partners Healthcare Company Showcase, taking place Wednesday, May 21, 2025. globenewswire.com - 1 month ago
Assertio Holdings, Inc. (ASRT) Q1 2025 Earnings Call Transcript Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Matt Kreps - Investor Relations Brendan O'Grady - Chief Executive Officer Ajay Patel - Chief Financial Officer. Conference Call Participants Thomas Flaten - Lake Street Naz Rahman - Maxim Group Ram Selvaraju - H.C. seekingalpha.com - 1 month ago
Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates Assertio (ASRT) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.04 per share a year ago. zacks.com - 1 month ago
Assertio Reports First Quarter 2025 Financial Results First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook globenewswire.com - 1 month ago
Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025 LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans. globenewswire.com - 1 month ago
Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025 LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the iAccess Alpha Best Ideas Spring Investment Conference taking place virtually March 25-26, 2025. globenewswire.com - 3 months ago
Assertio Holdings, Inc. (ASRT) Q4 2024 Earnings Call Transcript Assertio Holdings, Inc. (NASDAQ:ASRT ) Q4 2024 Earnings Conference Call March 12, 2025 4:30 PM ET Company Participants Matthew Kreps - IR Brendan O'Grady - CEO Ajay Patel - CFO Conference Call Participants James Sidoti - Sidoti & Company Thomas Flaten - Lake Street Capital Markets, LLC Naz Rahman - Maxim Group Scott Henry - AGP Operator Thank you for standing by. My name is Eric, and I'll be your conference operator today. seekingalpha.com - 3 months ago
Assertio Reports Fourth Quarter and Full Year 2024 Financial Results Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of $26.4 Million, Cash and Investments Increases to $100.1 Million LAKE FOREST, Ill., March 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today reported financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 3 months ago
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025 LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. globenewswire.com - 3 months ago
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Assertio Holdings, Inc. (NASDAQ: ASRT); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel CHICAGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed in Lake County Circuit Court, Nineteenth Judicial Circuit, State of Illinois, on behalf of all persons and entities who acquired Assertio Holdings, Inc. (NASDAQ: ASRT) (“Assertio” or the “Company”) common stock issued in exchange for Spectrum Pharmaceuticals, Inc. (“Spectrum”) common stock in connection with Assertio's July 31, 2023 merger with Spectrum (the “Merger”), charging the Company and certain of its current and former senior executives and directors with violations of the federal securities laws (collectively, “Defendants”). globenewswire.com - 4 months ago
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective December 23, 2024, the Compensation Committee of the Company's Board of Directors granted Mary Pietryga, the Company's newly-hired Senior Vice President, Chief Commercial Officer, 62,500 restricted stock units (“RSUs”) and 275,000 stock options (“options”). globenewswire.com - 5 months ago
8. Profile Summary

Assertio Holdings, Inc. ASRT

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 60.3 M
Dividend Yield 0.00%
Description Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
Contact 100 South Saunders Road, Lake Forest, IL, 60045 https://www.assertiotx.com
IPO Date Dec. 3, 1997
Employees 58
Officers Mr. Paul Schwichtenberg Executive Vice President & Chief Transformation Officer Mr. Bill Iskos Senior Vice President of Operations Ms. Molly Dir Senior Vice President of HR & Administration Mr. Brendan P. O'Grady Chief Executive Officer & Director Mr. Sam Schlessinger Executive Vice President & General Counsel Ms. Mary Pietryga Executive Vice President & Chief Commercial Officer Mr. Ajay Patel Executive Vice President & Chief Financial Officer Dr. Howard J. Franklin M.B.A., M.D. Senior Vice President of Medical